Status:
WITHDRAWN
Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects
Lead Sponsor:
Emma Nilsson
Collaborating Sponsors:
Göteborg University
Uppsala University Hospital
Conditions:
Ascites
Cirrhosis
Eligibility:
MALE
18-70 years
Phase:
PHASE2
Brief Summary
This study compares Spironolactone, a non-selective aldosterone antagonist, with Eplerenone, a selective aldosterone antagonist, regarding efficacy and hormonal side effects when treating male cirrhot...
Eligibility Criteria
Inclusion
- Male Ascites Cirrhosis
- \-
Exclusion
- Prior treatment with aldosterone antagonist Uncontrolled heart disease or diabetes Current malignancy Current medication interacting with aldosterone antagonists
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01801228
Start Date
February 1 2013
End Date
October 1 2015
Last Update
January 15 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Skane
Lund, Skåne County, Sweden, 221 85